Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →What's hot!
View all perspectives
What's Hot
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical settings. Two EULAR 2026 abstracts highlight the evolving role of LLMs across this spectrum, from patient-facing education to diagnostic reasoning.
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
Psoriatic arthritis develops in approximately 20 to 30 per cent of patients with psoriasis, yet predicting which patients will make the transition and when, has remained one of the most clinically challenging questions in rheumatology. A study presented at EULAR 2026 provides the most granular ultrasound characterisation yet of the journey from psoriasis, through subclinical disease, to early clinical PsA. The study identifies the specific
Dr. Sun et al. from Duke University presented abstract POS0692 during one of the poster sessions entitled, “Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers.” They evaluated differences in self-reported medication adherence and reasons for nonadherence across Type 1 & 2 SLE classification groups, with a prespecified focus on comparing
Imaging in the preclinical phase of RA is moving fast—arguably faster than our ability to interpret what we are actually seeing. Across EULAR 2026 abstracts, a consistent theme emerges: we are improving detection of subclinical inflammation, but still struggling to determine what level of detection is clinically meaningful.
MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.
Across EULAR 2026 abstracts this year and presented in a session called “this is a woman’s world”, strong signals are emerging that the menopausal transition is associated with changes in disease phenotype, disease activity, and treatment response in both RA and PsA.
The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and classification criteria for the Anti-Synthetase Syndrome. Here are but a few of my favorites from a list of many quality sessions.
B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.
At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.
Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs. EULAR is focused on systemic sclerosis as the rheumatic disease with the highest morbidity and mortality. New data presented at the EULAR 2026 Congress underscore key complications, and offer hope for a possible new therapeutic strategy.
